Señales en vivo de CGEN | Maximiza tus Ganancias con Getagraph.com

VENDER 123506 min ago

@ $2.22

Emitido: 14 feb 2024 @ 09:33

Retorno: -5.86%

Señal anterior: feb 13 - 15:01

Señal anterior: Comprar

Retorno: 1.14 %

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 16:00):

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe...

Stats
Volumen de hoy	106 600
Volumen promedio	476 685
Capitalización de mercado	187.12M
EPS	$0 ( 2024-03-05 )
Próxima fecha de ganancias	( $-0.100 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.95
ATR14	$0.00300 (0.14%)

Volumen Correlación

Largo: 0.18 (neutral)

Corto: 0.25 (neutral)

Signal:(58.752) Neutral

Compugen Ltd Correlación

10 Correlaciones Más Positivas
ENTG	0.933
ADSE	0.932
KOPN	0.93
CTIC	0.926
RMBL	0.917
ALR	0.916
MVIS	0.914
MRAM	0.913
NWLI	0.912
ORGO	0.912

10 Correlaciones Más Negativas
ULTA	-0.945
SBNYP	-0.915
HOLUU	-0.904
EMBCV	-0.899
TTCF	-0.889
OPTN	-0.888
CDAK	-0.884
CPRX	-0.88
PHCF	-0.87
BNIXU	-0.87

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Compugen Ltd Correlación - Moneda/Commodity

0.68
( moderate )

0.14
( neutral )

0.00
( neutral )

-0.62
( weak negative )

Compugen Ltd Finanzas

Annual	2023
Ingresos:	$33.46M
Beneficio Bruto:	$30.98M (92.59 %)
EPS:	$-0.210

FY	2023
Ingresos:	$33.46M
Beneficio Bruto:	$30.98M (92.59 %)
EPS:	$-0.210

FY	2022
Ingresos:	$7.50M
Beneficio Bruto:	$6.53M (87.00 %)
EPS:	$-0.390

FY	2021
Ingresos:	$6.00M
Beneficio Bruto:	$5.32M (88.67 %)
EPS:	$-0.410

Financial Reports:

No articles found.

Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.